M N Ehsan

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.

B L Lum, Sonja Kaubisch, Alan M. Yahanda et al. · Journal of Clinical Oncology · 1992 · 301 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.

Nancy L. Bartlett, B L Lum, George A. Fisher et al. · Journal of Clinical Oncology · 1994 · 188 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.

Derick Lau, Alexander D. Lewis, M N Ehsan et al. · PubMed · 1991 · 97 citations

Medicine, Oncology, Pharmacology +17

Dissociation of Antitumor Potency from Anthracycline Cardiotoxicity in a Doxorubicin Analog

Branimir I. Šikić, M N Ehsan, W G Harker et al. · Science · 1985 · 48 citations

Medicine, Oncology, Pharmacology +13

High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group.

Branimir I. Šikić, Sidney Scudder, Samuel C. Ballon et al. · PubMed · 1986 · 48 citations

Medicine, Gynecology, Oncology +11